Cited by 217MicroRNA in disease regulationNeuroinflammation and Neurodegeneration MechanismsAcute Ischemic Stroke Management

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

An Antagomir to MicroRNA Let7f Promotes Neuroprotection in an Ischemic Stroke Model

Open access

Abstract

We previously showed that middle-aged female rats sustain a larger infarct following experimental stroke as compared to younger female rats, and paradoxically, estrogen treatment to the older group is neurotoxic. Plasma and brain insulin-like growth factor-1 (IGF-1) levels decrease with age. However, IGF-1 infusion following stroke, prevents estrogen neurotoxicity in middle-aged female rats. IGF1 is neuroprotective and well tolerated, but also has potentially undesirable side effects. We hypothesized that microRNAs (miRNAs) that target the IGF-1 signaling family for translation repression could be alternatively suppressed to promote IGF-1-like neuroprotection. Here, we report that two conserved IGF pathway regulatory microRNAs, Let7f and miR1, can be inhibited to mimic and even extend the neuroprotection afforded by IGF-1. Anti-mir1 treatment, as late as 4 hours following ischemia, significantly reduced cortical infarct volume in adult female rats, while anti-Let7 robustly reduced both cortical and striatal infarcts, and preserved sensorimotor function and interhemispheric neural integration. No neuroprotection was observed in animals treated with a brain specific miRNA unrelated to IGF-1 (anti-miR124). Remarkably, anti-Let7f was only effective in intact females but not males or ovariectomized females indicating that the gonadal steroid environment critically modifies miRNA action. Let7f is preferentially expressed in microglia in the ischemic hemisphere and confirmed in ex vivo cultures of microglia obtained from the cortex. While IGF-1 was undetectable in microglia harvested from the non-ischemic hemisphere, IGF-1 was expressed by microglia obtained from the ischemic cortex and was further elevated by anti-Let7f treatment. Collectively these data support a novel miRNA-based therapeutic strategy for neuroprotection following stroke.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0032662

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 79 references

Cited by

Sorted by citations

Items 101–200 of 217

Metadata

Authors
Selvamani, A., Sathyan, P., Miranda, R. C., & Sohrabji, F.
Affiliations
Texas A&M Health Science Center (US)
Corresponding author
Sohrabji, Farida
Venue
PLoS ONE
Published
2012-02-29
Volume
7
Issue
2
Pages
e32662
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2071432376
Cited by
217
References
79
Citations by year
2026: 1 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 16 · 2019: 19 · 2018: 18 · 2017: 26 · 2016: 20 · 2015: 23 · 2014: 27 · 2013: 22 · 2012: 4
FWCI
8.02
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • OakTrust (Texas A&M University Libraries) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (R01AG027684, AG027684, AG028303, R01AG028303)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
ischemic stroke, neuroprotection, microRNA, let-7f, miR-1, insulin-like growth factor I, IGF-1 signaling, microglia, sex differences, infarct size, sensorimotor function, hemispheric integration, sex steroids
MeSH terms
Animals, Behavior, Animal, Disease Models, Animal, Female, Gene Expression Regulation, Insulin-Like Growth Factor I, Ischemia, Male, Sex Factors, Reperfusion Injury, Microglia, Neuroprotective Agents, Stroke, MicroRNAs, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review